» Articles » PMID: 15178554

Thrombomodulin-protein C-EPCR System: Integrated to Regulate Coagulation and Inflammation

Overview
Date 2004 Jun 5
PMID 15178554
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Late in the 18th century, William Hewson recognized that the formation of a clot is characteristic of many febrile, inflammatory diseases (Owen C. A History of Blood Coagulation. Rochester, Minnesota: Mayo Foundation; 2001). Since that time, there has been steady progress in our understanding of coagulation and inflammation, but it is only in the past few decades that the molecular mechanisms linking these 2 biologic systems have started to be delineated. Most of these can be traced to the vasculature, where the systems most intimately interact. Thrombomodulin (TM), a cell surface-expressed glycoprotein, predominantly synthesized by vascular endothelial cells, is a critical cofactor for thrombin-mediated activation of protein C (PC), an event further amplified by the endothelial cell protein C receptor (EPCR). Activated PC (APC), in turn, is best known for its natural anticoagulant properties. Recent evidence has revealed that TM, APC, and EPCR have activities that impact not only on coagulation but also on inflammation, fibrinolysis, and cell proliferation. This review highlights recent insights into the diverse functions of this complex multimolecular system and how its components are integrated to maintain homeostasis under hypercoagulable and/or proinflammatory stress conditions. Overall, the described advances underscore the usefulness of elucidating the relevant molecular pathways that link both systems for the development of novel therapeutic and diagnostic targets for a wide range of inflammatory diseases.

Citing Articles

In-depth proteomic profiling identifies potentiation of the LPS response by 7-ketocholesterol.

Phair I, Sovakova M, Alqurashi N, Nisr R, McNeilly A, Lamont D J Mol Cell Cardiol Plus. 2025; 11:100285.

PMID: 39991505 PMC: 11847031. DOI: 10.1016/j.jmccpl.2025.100285.


Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor.

Zhang H, Diao X, Jiang T, Wei M, Su Y, Shen J Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459040 PMC: 11510285. DOI: 10.3390/ph17101401.


Protective roles of thrombomodulin in cisplatin-induced nephrotoxicity through the inhibition of oxidative and endoplasmic reticulum stress.

Yamamoto H, Ishida Y, Zhang S, Osako M, Nosaka M, Kuninaka Y Sci Rep. 2024; 14(1):14004.

PMID: 38890434 PMC: 11189513. DOI: 10.1038/s41598-024-64619-y.


Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes.

Russo I, Griffith Brookles C, Barale C, Melchionda E, Mousavi A, Biole C Int J Mol Sci. 2024; 25(7).

PMID: 38612792 PMC: 11011739. DOI: 10.3390/ijms25073981.


Endothelial Protein C Receptor and Its Impact on Rheumatic Disease.

OHehir Z, Lynch T, ONeill S, March L, Xue M J Clin Med. 2024; 13(7).

PMID: 38610795 PMC: 11012567. DOI: 10.3390/jcm13072030.